Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, Tan DSW, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Houvras Y, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Kong S, Zalutskaya A, Louie-Gao M, Boral AL, Mazières J. Griesinger F, et al. Among authors: misch d. Ann Oncol. 2022 Nov;33(11):1168-1178. doi: 10.1016/j.annonc.2022.08.002. Epub 2022 Aug 13. Ann Oncol. 2022. PMID: 35973665 Free article. Clinical Trial.
The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
Christopoulos P, Kluck K, Kirchner M, Lüders H, Roeper J, Falkenstern-Ge RF, Szewczyk M, Sticht F, Saalfeld FC, Wesseler C, Hackanson B, Dintner S, Faehling M, Kuon J, Janning M, Kauffmann-Guerrero D, Kazdal D, Kurz S, Eichhorn F, Bozorgmehr F, Shah R, Tufman A, Wermke M, Loges S, Brueckl WM, Schulz C, Misch D, Frost N, Kollmeier J, Reck M, Griesinger F, Grohé C, Hong JL, Lin HM, Budczies J, Stenzinger A, Thomas M. Christopoulos P, et al. Among authors: misch d. Eur J Cancer. 2022 Jul;170:106-118. doi: 10.1016/j.ejca.2022.04.020. Epub 2022 May 20. Eur J Cancer. 2022. PMID: 35598358
Landscape of Genomic Alterations and PD-L1 Expression in Early-Stage Non-Small-Cell Lung Cancer (NSCLC)-A Single Center, Retrospective Observational Study.
Stephan-Falkenau S, Streubel A, Mairinger T, Kollmeier J, Misch D, Thiel S, Bauer T, Pfannschmidt J, Hollmann M, Wessolly M, Blum TG. Stephan-Falkenau S, et al. Among authors: misch d. Int J Mol Sci. 2022 Oct 19;23(20):12511. doi: 10.3390/ijms232012511. Int J Mol Sci. 2022. PMID: 36293366 Free PMC article.
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.
Griesinger F, Curigliano G, Subbiah V, Baik CS, Tan DS, Lee DH, Misch D, Garralda E, Kim DW, van der Wekken AJ, Gainor JF, Paz-Ares L, Liu SV, Kalemkerian GP, Bowles DW, Mansfield AS, Lin JJ, Smoljanovic V, Rahman A, Zalutskaya A, Louie-Gao M, Boral AL, Mazières J. Griesinger F, et al. Among authors: misch d. Future Oncol. 2024 Feb;20(6):297-306. doi: 10.2217/fon-2023-0155. Epub 2023 Nov 2. Future Oncol. 2024. PMID: 37916501
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Among authors: misch d. Eur J Cancer. 2024 Mar;199:113556. doi: 10.1016/j.ejca.2024.113556. Epub 2024 Jan 17. Eur J Cancer. 2024. PMID: 38271745 Free article.
Corrigendum to "First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations" [Eur J Cancer 199 (2024) 113556].
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Among authors: misch d. Eur J Cancer. 2024 Jul;205:114130. doi: 10.1016/j.ejca.2024.114130. Epub 2024 May 24. Eur J Cancer. 2024. PMID: 38789333 No abstract available.
Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M, Mairinger F, Reis H, Goetz M, Kollmeier J, Misch D, Stephan-Falkenau S, Mairinger T, Walter RFH, Hager T, Metzenmacher M, Eberhardt WEE, Zaun G, Köster J, Stuschke M, Aigner C, Darwiche K, Schmid KW, Rahmann S, Schuler M. Wiesweg M, et al. Among authors: misch d. Eur J Cancer. 2020 Nov;140:76-85. doi: 10.1016/j.ejca.2020.09.015. Epub 2020 Oct 12. Eur J Cancer. 2020. PMID: 33059196
Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids.
Frost N, Kollmeier J, Misch D, Vollbrecht C, Grah C, Matthes B, Pultermann D, Olive E, Raspe M, Ochsenreither S, von Laffert M, Suttorp N, Witzenrath M, Grohé C. Frost N, et al. Among authors: misch d. Clin Lung Cancer. 2021 Sep;22(5):411-422. doi: 10.1016/j.cllc.2021.02.001. Epub 2021 Feb 6. Clin Lung Cancer. 2021. PMID: 33648877
69 results